Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nxera Pharma CoSTU:JSS -2.94%82 Interest Coverage is 7.79 as of Jun. 2026, which is 499% above its 10-year median of 1.30. GuruFocus rates STU:JSS with a GF Score™ of 82/100 and a GF Value™ of €6.08. The stock has 9 warning signs investors should review. Among 368 Biotechnology companies, Nxera Pharma Co ranks worse than 271738.86% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Nxera Pharma Co's
Operating Income
for the
three
months ended in Jun. 2026 was €22.0 Mil. Nxera Pharma Co's Interest Expense for the
three
months ended in Jun. 2026 was €-2.8 Mil.
Nxera Pharma Co's interest coverage for the quarter that ended in Jun. 2026 was 7.79.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Nxera Pharma Co's Interest Coverage or its related term are showing as below:
STU:JSS's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 98.255 * Ranked among companies with meaningful Interest Coverage only.
Nxera Pharma Co (STU:JSS) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Nxera Pharma Co Interest Coverage Related Terms
Nxera Pharma Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Nxera Pharma Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
STU:JSS vs VRTX, REGN, MRNA: Interest Coverage Comparison
For the Biotechnology subindustry, Nxera Pharma Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nxera Pharma Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Nxera Pharma Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nxera Pharma Co (STU:JSS) has a Interest Coverage of 7.79 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Nxera Pharma Co and its competitors. This is 499% above median its historical median of 1.30. According to the industry distribution chart, Nxera Pharma Co ranks #999999 out of 368 companies in the Biotechnology industry.
Is Nxera Pharma Co's Interest Coverage too high?
Nxera Pharma Co's current Interest Coverage of 7.79 is 499% above median its 10-year median of 1.30. The Biotechnology industry median Interest Coverage is 98.26. Nxera Pharma Co's value of 7.79 is 92.1% below this industry median. Based on the distribution chart, Nxera Pharma Co ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nxera Pharma Co has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nxera Pharma Co ranks #999999 out of 368 companies for Interest Coverage. This places Nxera Pharma Co in the lower half of its industry. The industry median Interest Coverage is 98.26. Nxera Pharma Co's value of 7.79 is 92.1% below this benchmark. While the company's 10-year median is 1.30 vs. the industry median of 98.26, Nxera Pharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 98.26, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nxera Pharma Co's current Interest Coverage of 7.79 is 92.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Nxera Pharma Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 98.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nxera Pharma Co's current Interest Coverage is 7.79, which is 499% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Nxera Pharma Co (STU:JSS) has a current Interest Coverage of 7.79. The stock's GF Value™ is €6.08, compared to a current price of €6.60 — trading 8.6% above its estimated fair value. The current Interest Coverage is 7.79, which is 499% above median its 10-year median of 1.30 and 92.1% below the Biotechnology industry median of 98.26. Nxera Pharma Co's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Nxera Pharma Co (STU:JSS), the current Interest Coverage is 7.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nxera Pharma Co (STU:JSS) Overvalued in 2026?
Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be overvalued.
The current stock price of €6.60 is trading 8.6% above its estimated GF Value™ of €6.08.
Key valuation signals for STU:JSS:
Interest Coverage: 7.79 (499% above median its 10-year median of 1.30)
GF Value™: €6.08 vs. price of €6.60 (8.6% above fair value)
Industry Position: 92.1% below the Biotechnology median (#999999 of 368)
No single metric tells the full story. See the STU:JSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
82GF Score
Get the complete analysis for STU:JSS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:JSS has been successfully added to your 
